MTOR and breast carcinoma: Thus, there is a rationale to treat patients with a combination of chemotherapeutics that induce DNA damage and mTOR inhibitors, like rapamycin, due to additive cytotoxic effects in breast carcinoma cell lines (Mondesire et al., 2004).